Zenith Capital Corp. (ZHCLF)

OTCMKTS · Delayed Price · Currency is USD
0.0800
0.00 (0.00%)
At close: Mar 5, 2026
-20.00%
Market Cap 12.78M
Revenue (ttm) 500.00K
Net Income (ttm) -6.82M
Shares Out 159.73M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,000
Average Volume 20,214
Open 0.0800
Previous Close n/a
Day's Range 0.0800 - 0.0800
52-Week Range 0.0001 - 0.1500
Beta 691.93
RSI 49.57
Earnings Date Apr 6, 2026

About Zenith Capital

Zenith Capital Corp., a biotechnology investment company, engages in the development of bromodomain inhibitors for the treatment of cancer and other disorders with unmet medical needs. The company’s lead compound ZEN-3694, which is in Phase 2 clinical trial for the treatment of metastatic castration resistant prostate cancer in collaboration with Astellas and Newsoara, as well as advanced or metastatic triple-negative breast cancer in collaboration with Pfizer. It has a research and development collaboration agreement with the National Cancer I... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Country Canada
Stock Exchange OTCMKTS
Ticker Symbol ZHCLF
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.